NASDAQ:ARVN
Arvinas Inc. Stock News
$35.95
+1.30 (+3.75%)
At Close: May 22, 2024
Expert Ratings For Arvinas
06:10pm, Wednesday, 06'th Apr 2022 Benzinga
Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
2
1
0
0
Last 30D
0
0
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
02:16pm, Wednesday, 06'th Apr 2022 Benzinga
Upgrades
According to Morgan Stanley, the prior rating for Royalty Pharma PLC (NASDAQ:RPRX) was changed from Equal-Weight to Overweight. In the fourth quarter, Royalty Pharma showed an EPS of $0.80, c
Things To Consider Before Buying Arvinas Inc. (NASDAQ: ARVN)
01:30pm, Saturday, 12'th Mar 2022 Stocks Register
Arvinas Inc. (NASDAQ:ARVN) shares, rose in value on Friday, 03/11/22, with the stock price down by -0.53% to the previous day’s close as strong demand from buyers drove the stock to $68.21. Actively observing the price movement in the last trading, the stock closed the session at $68.57, falling within a range of $67.685 and … Things To Consider Before Buying Arvinas Inc. (NASDAQ: ARVN) Read More »
Arvinas to Present at Upcoming Investor Conferences
12:00pm, Friday, 04'th Mar 2022 GlobeNewswire Inc.
NEW HAVEN, Conn., March 04, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today a
Arvinas to Present at Upcoming Investor Conferences
07:00am, Friday, 04'th Mar 2022
NEW HAVEN, Conn., March 04, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann
Epizyme (EPZM) Q4 Loss Wider Than Expected, Revenues Lag
04:22pm, Wednesday, 02'nd Mar 2022 Zacks Investment Research
Epizyme (EPZM) posts a wider-than-expected loss for the fourth quarter. Revenues also miss estimates. Nevertheless, the pipeline progress is encouraging.
Axsome (AXSM) Posts Narrower-Than-Expected Q4 Loss
04:16pm, Wednesday, 02'nd Mar 2022 Zacks Investment Research
Axsome Therapeutics (AXSM) reports a narrower-than-expected Q4 loss. The company is actively preparing to support the commercial launch of its two under-review candidates, AXS-05 and AXS-07.
Where Arvinas Stands With Analysts
02:09pm, Tuesday, 01'st Mar 2022 Benzinga
Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
2
0
0
0
Last 30D
1
0
Where Arvinas Stands With Analysts
02:09pm, Tuesday, 01'st Mar 2022 Benzinga
Arvinas (NASDAQ: ARVN ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 2 0 0 0 2M Ago 1 0 0 0 0 3M Ago 0 0 0 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, Arvinas has an average price target of $114.0 with a high of $157.00 and a low of $91.00. Below is a summary of how these 4 analysts rated Arvinas over the past 3 months. The greater the number of bullish ratings, the more positive analysts are … Full story available on Benzinga.com
Arvinas: Q4 Earnings Insights
01:28pm, Monday, 28'th Feb 2022 Benzinga
Arvinas (NASDAQ: ARVN ) reported its Q4 earnings results on Monday, February 28, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Arvinas missed estimated earnings by 26.58%, reporting an EPS of $-1.0 versus … Full story available on Benzinga.com
Arvinas, Inc. (ARVN) Reports Q4 Loss, Tops Revenue Estimates
01:25pm, Monday, 28'th Feb 2022 Zacks Investment Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -28.21% and 40.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Arvinas GAAP EPS of -$1.00 misses by $0.21, revenue of $26.3M beats by $11.22M
12:16pm, Monday, 28'th Feb 2022 Seeking Alpha
Arvinas press release (NASDAQ:ARVN): Q4 GAAP EPS of -$1.00 misses by $0.21.Revenue of $26.3M (+1095.5% Y/Y) beats by $11.22M.
Arvinas Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
12:00pm, Monday, 28'th Feb 2022 GlobeNewswire
NEW HAVEN, Conn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.
Arvinas, Inc. (ARVN) Reports Q4 Loss, Tops Revenue Estimates
09:59am, Monday, 28'th Feb 2022
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -28.21% and 40.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Arvinas Inc. (NASDAQ:ARVN) Projected To Shrink By -151.93% Or More
05:00pm, Saturday, 26'th Feb 2022 Marketing Sentinel
In last trading session, Arvinas Inc. (NASDAQ:ARVN) saw 0.66 million shares changing hands with its beta currently measuring 2.00. Company’s recent per share price level of $67.48 trading at $1.15 or 1.73% at ring of the bell on the day assigns it a market valuation of $3.59B. That closing price of ARVN’s stock is at … Arvinas Inc. (NASDAQ:ARVN) Projected To Shrink By -151.93% Or More Read More »